Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | President and COO | August 25, 2026 | August 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date August 25, 2026 · Filed August 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-25 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2026-08-25 · Sale · Disposed 280 · Balance 0 F1: Each American Depositary Share represents 13 Ordinary Shares. F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. |
| American Depositary SharesSEC Table I · non-derivative | Direct | 12,365 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,365 F1: Each American Depositary Share represents 13 Ordinary Shares. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,270,084 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,270,084 |
| American Depositary SharesSEC Table I · non-derivative | IndirectBy Wife | 4,000 |
Reported balance
Holding disclosure · report date 2026-08-25 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,000 F1: Each American Depositary Share represents 13 Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2025 Filed Jun 18, 2025 21:08 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 1,443 | $265.47 | $383,072.49 |
DisclosureSEC source: 0001651308-25-000112 · wk-form4_1750280880.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.21 to $266.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:42 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 232,245 | $0.00 Strike: $20.26 | $0.00 |
DisclosureSEC source: 0001651308-25-000106 · wk-form4_1749764515.xml · derivative · entry 4 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,245 Underlying: Ordinary Shares · 232,245 shares Expires 2035-06-09 F3 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F3 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. F4 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 10, 2025 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:42 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | GrantOrdinary Shares | 123,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000106 · wk-form4_1749764515.xml · nonDerivative · entry 1 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,274,296 F1 · security: Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 234 | $255.77 | $59,850.02 |
DisclosureSEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.67 to $255.8887, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 400 | $255.31 | $102,122.00 |
DisclosureSEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 234 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.60 to $255.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 400 | $253.50 | $101,399.00 |
DisclosureSEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.31 to $253.81, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 500 | $251.85 | $125,926.00 |
DisclosureSEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,034 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.585 to $252.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:55 UTC | BeOne Medicines Ltd. ONC · Entity 2168 | SaleAmerican Depositary Shares | 400 | $250.74 | $100,294.00 |
DisclosureSEC source: 0001651308-25-000101 · wk-form4_1749588905.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,534 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F2 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 5, 2024, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.56 to $251.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 460,772 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · derivative · entry 11 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,049 Underlying: Ordinary Shares · 460,772 shares Expires 2030-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F10 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on June 17, 2021 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 214,201 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · derivative · entry 10 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 214,201 shares Expires 2029-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F9 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,083 | $283.79 | $1,442,520.84 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 9 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.12 to $284.10, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 12,221 | $282.76 | $3,455,640.51 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,083 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.03 to $283.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,364 | $281.67 | $1,792,570.79 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,304 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.01 to $282.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 28,253 | $280.31 | $7,919,637.98 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,668 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F3 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.00 to $280.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 35,444 | $174.43 | $6,182,496.92 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 16,477 | $119.96 | $1,976,580.92 |
DisclosureSEC source: 0001651308-25-000053 · wk-form4_1743714287.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:51 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleRMB Shares | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000051 · wk-form4_1742331075.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market. F3 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F5 · shares: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB7,657,022 (or US$1,057,600 based on an exchange rate of US$1.00 = RMB7.24) for such disposal. F5 · price: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB7,657,022 (or US$1,057,600 based on an exchange rate of US$1.00 = RMB7.24) for such disposal. F3 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F4 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 583,349 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · derivative · entry 12 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 214,201 Underlying: Ordinary Shares · 583,349 shares Expires 2029-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 91,624 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · derivative · entry 11 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2 Underlying: Ordinary Shares · 91,624 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $263.00 | $52,600.00 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 10 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 22,537 | $262.51 | $5,916,235.20 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 9 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.00 to $262.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 11,360 | $261.61 | $2,971,881.65 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,737 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.00 to $261.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 17,824 | $260.39 | $4,641,187.80 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,097 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.00 to $260.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 44,873 | $119.96 | $5,382,965.08 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 7,048 | $169.65 | $1,195,693.20 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantOrdinary Shares | 103,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000046 · wk-form4_1741393434.xml · nonDerivative · entry 1 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,175,210 F1 · shares: Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested securities are subject to accelerated vesting upon certain termination events. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:17 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleRMB Shares | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-25-000038 · wk-form4_1741126625.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market. F3 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F5 · shares: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB8,445,965 (or US$1,161,756 based on an exchange rate of US$1.00 = RMB7.27) for such disposal. F5 · price: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB8,445,965 (or US$1,161,756 based on an exchange rate of US$1.00 = RMB7.27) for such disposal. F3 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F4 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 276,471 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · derivative · entry 12 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,626 Underlying: Ordinary Shares · 276,471 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 21,267 | $240.07 | $5,105,513.40 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 10 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| February 20, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 21,267 | $169.65 | $3,607,946.55 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 9 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionShare Option (Right to Buy) · Derivative | 398,502 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · derivative · entry 11 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 368,097 Underlying: Ordinary Shares · 398,502 shares Expires 2028-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. The exercise price is equal to 1/13 of the closing price of our ADSs on the date of grant, as each ADS represents 13 ordinary shares. F11 · derivative.exercise_date: These securities vest over a five-year period as follows: 20% on April 30, 2019, and the remaining in 48 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,159 | $242.08 | $764,728.82 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.00 to $242.28, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,919 | $241.26 | $1,910,558.53 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,159 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $241.00 to $241.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 19,576 | $240.31 | $4,704,243.96 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,078 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $240.00 to $240.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 23:12 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | Exercise / conversionAmerican Depositary Shares | 30,654 | $169.65 | $5,200,451.10 |
DisclosureSEC source: 0001651308-25-000018 · wk-form4_1740093141.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each American Depositary Share represents 13 Ordinary Shares. Read SEC document |
| December 06, 2024 Filed Dec 11, 2024 01:19 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleRMB Shares | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001651308-24-000165 · wk-form4_1733879987.xml · nonDerivative · entry 4 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F2 · security: The term "RMB Shares" is used herein to represent the ordinary shares, par value $0.0001 per share, of the Issuer, issued directly by the Issuer in the Issuer's initial public offering on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange (the "STAR Offering"), to permitted investors in Renminbi ("RMB") within the People's Republic of China ("PRC") in accordance with the rules of the STAR Market. F3 · shares: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4 · shares: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F5 · shares: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB878,900 (or US$120,894 based on an exchange rate of US$1.00 = RMB7.27) for such disposal. F5 · price: The Reporting Person disposed of a portion of his economic interest in the RMB Shares Employee Participation Plan and expects to receive net proceeds of approximately RMB878,900 (or US$120,894 based on an exchange rate of US$1.00 = RMB7.27) for such disposal. F3 · balance_after: The Issuer established an employee participation program ("RMB Shares Employee Participation Plan"), which allows certain executive officers and qualified employees of the Issuer's subsidiaries in the PRC to indirectly participate in the STAR Offering and purchase certain RMB Shares from the Issuer through an asset management plan administrated by China International Capital Corporation Limited in a transaction that is exempt under Rule 16b-3. The RMB Share Employee Participation Plan purchased an aggregate of 2,069,546 RMB Shares directly from the Issuer in the STAR Offering at the initial public offering price of RMB192.6 per RMB Share (or $30.1295 based on an assumed exchange rate of $1.00 = RMB6.3924). F4 · balance_after: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. F4 · ownership.nature: The Reporting Person, as an individual participant in the RMB Shares Employee Participation Plan, contributed RMB15 million to the RMB Shares Employee Participation Plan upon the establishment of the RMB Shares Employee Participation Plan. The Reporting Person may be deemed to have indirect economic interest in an indeterminable portion of the RMB Shares held by the RMB Shares Employee Participation Plan but does not have voting or dispositive power over any of such shares. The Reporting Person disclaims Section 16 beneficial ownership of the RMB Shares held by the RMB Shares Employee Participation Plan, except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such RMB Shares for Section 16 or any other purpose. Read SEC document |
| September 19, 2024 Filed Sep 19, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,500 | $200.14 | $900,614.70 |
DisclosureSEC source: 0001651308-24-000115 · wk-form4_1726781110.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 500 | $200.00 | $100,000.00 |
DisclosureSEC source: 0001651308-24-000115 · wk-form4_1726781110.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,500 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 274 | $192.04 | $52,619.92 |
DisclosureSEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 9 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.89 to $192.17, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 700 | $191.20 | $133,843.43 |
DisclosureSEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 274 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.86 to $191.57, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,275 | $190.29 | $432,908.61 |
DisclosureSEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 974 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.85 to $190.82, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 275 | $188.97 | $51,967.74 |
DisclosureSEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,249 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.85 to $189.81, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:41 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,032 | $188.16 | $382,337.06 |
DisclosureSEC source: 0001651308-24-000112 · wk-form4_1725572488.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,524 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.78 to $188.64, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 23 | $161.27 | $3,709.21 |
DisclosureSEC source: 0001651308-24-000077 · wk-form4_1719437065.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 400 | $160.38 | $64,151.28 |
DisclosureSEC source: 0001651308-24-000077 · wk-form4_1719437065.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.16 to $161.0328, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 21:24 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,036 | $159.53 | $165,272.77 |
DisclosureSEC source: 0001651308-24-000077 · wk-form4_1719437065.xml · nonDerivative · entry 5 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 423 F1 · security: Each American Depositary Share represents 13 Ordinary Shares. F5 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 22, 2022, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.13 to $159.795, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $156.80 | $47,040.99 |
DisclosureSEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 9 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F10 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.61 to $156.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $155.15 | $46,544.76 |
DisclosureSEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 8 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F10 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.23, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 906 | $154.17 | $139,680.01 |
DisclosureSEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 7 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F10 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 15, 2023, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.00 to $154.42, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:25 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,121 | $153.66 | $172,250.06 |
DisclosureSEC source: 0001651308-24-000072 · wk-form4_1718918703.xml · nonDerivative · entry 6 Wu Xiaobin · CIK 0001739452 · President, COO & GM China 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,506 F2 · security: Each American Depositary Share represents 13 Ordinary Shares. F8 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.47 to $153.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.